Press Releases

Debiopharm and Ascenta Therapeutics, Inc. announce an exclusive license agreement for the development and commercialization of the IAP (Inhibitor of…

Debiopharm Group™ s’installe dans son “Espace «après-demain»” au sein du quartier de l’innovation de l’EPFL

INC Research and Debiopharm Group ™ announce Strategic Partnership

Continuity as Debiopharm Group™ management moves forward

Debiopharm and Yale announce an exclusive license agreement for the development and commercialization of Debio 1036, a first-in-class inhibitor for…

The Debiopharm Group and Marina Biotech Partner to Develop and Commercialise RNAi-based Therapies for the Treatment of Bladder Cancer

Diagnoplex Closes an Extension of Its Series A Financing with a substantial Investment by Debiopharm Group™

Frost & Sullivan Presents Debiopharm Group™ with “European Biopharmaceuticals Company of the Year Award”

Abionic wins the ‘Prix Debiopharm Valais pour les Sciences de la Vie’ for its innovative biomedical device for diagnostic testing